Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers

Two vaccines are licensed and recommended to prevent shingles in the U.S.  Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix) has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine.

Shingrix Information for Healthcare Professionals

Two vaccines are licensed and recommended to prevent shingles in the U.S.  Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix) has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine.

Zostavax Information for Healthcare Providers

CDC still recommends Zostavax® for healthy adults 60 years and older to prevent shingles. This shingles vaccine may be used in certain cases, such as when a person prefers Zostavax, is allergic to Shingrix, or requests immediate vaccination and Shingrix is unavailable.

Zostavax will no longer be sold in the United States starting July 1, 2020. Some pharmacies and clinics may still have Zostavax in stock. This vaccine is safe and may be used until the supply expires (before or by November 18, 2020).

Zostavax Recommendations

ACIP vaccine recommendations for people 60 years and older, vaccination of people 50-59 years old, and the contraindications and precautions

About the Vaccine

Information about vaccine composition, dosage, and administration as well as vaccine effectiveness and duration of protection

Storage and Handling

General information about vaccine storage and handling as well as Zostavax-specific storage practices and guidelines

Administering the Vaccine

Administering Zostavax with other vaccines and possible vaccine administration errors

References and Resources

Materials for patients and resources for providers

Page last reviewed: May 31, 2018